Atomwise Inc., a San Francisco, California-based developer of artificial intelligence systems for drug discovery, raised $6m in seed funding.
Backers included Data Collective, which led the funding, Khosla Ventures, DFJ, AME Cloud Ventures, OS Fund and Mission and Market.
The company intends to use the funds to grow operations and expand drug discovery collaborations from both private and public institutions.
Led by CEO Abraham Heifets, CTO Izhar Wallach, and COO Alexander Levy, Atomwise has developed drug research technology that learns like a human chemist, using deep learning algorithms and supercomputers to analyze millions of potential medicines each day. It can help predict the effectiveness of new medicines, reducing the need for costly and time-consuming physical synthesis and testing.
To date, Atomwise has been applied to research on more than a dozen disease targets including infectious diseases, neurological diseases, and cancers.
Have a look at clients here.
The company, a Y Combinator graduate, is actively recruiting in the areas of machine learning, computational biology, medicinal chemistry, business development, sales, marketing, and partnerships.